Literature DB >> 4758834

Tobramycin in bronchial secretions.

J E Pennington, H Y Reynolds.   

Abstract

The penetration of tobramycin sulfate (nebramycin factor 6) into normal lower respiratory tract secretions was studied in a dog model. After a 1.7 mg/kg intravenous dose of tobramycin, the antibiotic was detected promptly in bronchial secretions, but the peak bronchial secretion concentration was not usually reached until 2 h after injection (mean level 1.15 mug/ml). The maximum tobramycin concentration in bronchial fluids was equal to the mean inhibitory concentrations that have been reported for about 80% of Pseudomonas isolates.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4758834      PMCID: PMC444545          DOI: 10.1128/AAC.4.3.299

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Characteristics of nonbacteremic Pseudomonas pneumonia.

Authors:  J R Tillotson; A M Lerner
Journal:  Ann Intern Med       Date:  1968-02       Impact factor: 25.391

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Structure of nebramycin factor 6, a new aminoglycosidic antibiotic.

Authors:  K F Koch; J A Rhoades
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

4.  Concentrations of gentamicin and carbenicillin in bronchial secretions.

Authors:  J E Pennington; H Y Reynolds
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

5.  Tobramycin: in vitro activity and comparison with kanamycin and gentamicin.

Authors:  V E Del Bene; W E Farrar
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

6.  In vitro evaluation of tobramycin, a new aminoglycoside antibiotic.

Authors:  M E Levison; R Knight; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-05       Impact factor: 5.191

7.  Comparative activity of sisomicin, gentamicin, kanamycin, and tobramycin.

Authors:  J A Waitz; E L Moss; C G Drube; M J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

8.  Evaluation of the in vitro activity of tobramycin as compared with that of gentamicin sulfate.

Authors:  W H Traub; E A Raymond
Journal:  Appl Microbiol       Date:  1972-01

9.  In vitro studies of tobramycin.

Authors:  G P Bodey; D Stewart
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

  9 in total
  8 in total

Review 1.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

4.  Kinetic parameters of amikacin in cystic fibrosis children.

Authors:  B Grenier; E Autret; S Marchand; R Thompson
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

Review 5.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 7.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

8.  [Tobramycin Concentration in Human Lung Tissue (author's transl)].

Authors:  U Kroening; S Liebig; M Wundschock
Journal:  Infection       Date:  1978       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.